Neurocrine’s Crenessity Is The First New Drug For CAH In 70 Years

Next Competitor Likely Years Behind

 
• By Mandy Jackson
  
Neurocrine won FDA approval for Crenessity two weeks earlier than expected (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Drug Pricing

More from Market Access